155 related articles for article (PubMed ID: 19833261)
21. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
22. The pharmacogenomics of statins.
Gelissen IC; McLachlan AJ
Pharmacol Res; 2014 Oct; 88():99-106. PubMed ID: 24365577
[TBL] [Abstract][Full Text] [Related]
23. Iatrogenic myopathies.
Mastaglia FL
Curr Opin Neurol; 2010 Oct; 23(5):445-9. PubMed ID: 20581681
[TBL] [Abstract][Full Text] [Related]
24. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
25. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
26. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?
Kim RB
Clin Pharmacol Ther; 2004 May; 75(5):381-5. PubMed ID: 15116050
[No Abstract] [Full Text] [Related]
27. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.
Toms TE; Smith JP; Panoulas VF; Douglas KM; Saratzis AN; Kitas GD
Musculoskeletal Care; 2010 Mar; 8(1):2-9. PubMed ID: 19642078
[TBL] [Abstract][Full Text] [Related]
28. A current approach to statin intolerance.
Tompkins R; Schwartzbard A; Gianos E; Fisher E; Weintraub H
Clin Pharmacol Ther; 2014 Jul; 96(1):74-80. PubMed ID: 24727470
[TBL] [Abstract][Full Text] [Related]
29. Point-Counterpoint: SLCO1B1 Genotyping for Statins.
Wilke RA; Fanciullo J
S D Med; 2017 Mar; 70(3):102-104. PubMed ID: 28813770
[TBL] [Abstract][Full Text] [Related]
30. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.
Elsby R; Hilgendorf C; Fenner K
Clin Pharmacol Ther; 2012 Nov; 92(5):584-98. PubMed ID: 23047648
[TBL] [Abstract][Full Text] [Related]
31. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.
Vassy JL; Chun S; Advani S; Ludin SA; Smith JG; Alligood EC
Clin Pharmacol Ther; 2019 Aug; 106(2):360-373. PubMed ID: 30137643
[TBL] [Abstract][Full Text] [Related]
32. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
Peters BJ; Rodin AS; Klungel OH; van Duijn CM; Stricker BH; van't Slot R; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2010 Aug; 11(8):1065-76. PubMed ID: 20712525
[TBL] [Abstract][Full Text] [Related]
34. Seventeen years of statin pharmacogenetics: a systematic review.
Leusink M; Onland-Moret NC; de Bakker PI; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2016; 17(2):163-80. PubMed ID: 26670324
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
[TBL] [Abstract][Full Text] [Related]
36. Statin-induced myopathy SLCO1B1 521T > C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population.
Saber-Ayad M; Manzoor S; El-Serafi A; Mahmoud I; Abusnana S; Sulaiman N
Diabetes Res Clin Pract; 2018 May; 139():272-277. PubMed ID: 29534995
[TBL] [Abstract][Full Text] [Related]
37. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy.
Neřoldová M; Stránecký V; Hodaňová K; Hartmannová H; Piherová L; Přistoupilová A; Mrázová L; Vrablík M; Adámková V; Hubáček JA; Jirsa M; Kmoch S
Pharmacogenomics; 2016 Aug; 17(13):1405-14. PubMed ID: 27296017
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.
Yiannakopoulou ECh
Pharmacogenomics J; 2013 Apr; 13(2):105-9. PubMed ID: 23044602
[TBL] [Abstract][Full Text] [Related]
39. Role of genetic factors in statins side-effects.
Scarpini F; Cappellone R; Auteri A; Puccetti L
Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):35-43. PubMed ID: 22524173
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
Hopewell JC; Reith C; Armitage J
Curr Opin Lipidol; 2014 Dec; 25(6):438-45. PubMed ID: 25313593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
